for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started
completion around
Principal Investigator
by Nagasaka Misako



The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Official Title

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.


This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).


Non-Small-Cell Lung Cancer, Cancer, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Immune Checkpoint Inhibitors, CAB-AXL-ADC, PD-1 inhibitor, CAB-AXL-ADC (BA3011), CAB-AXL-ADC (BA3011)+PD-1 inhibitor


You can join if…

Open to people ages 18 years and up

  • Patients must have measurable disease.
  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.

You CAN'T join if...

  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3011
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.


  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center accepting new patients
    Irvine California 92868 United States
  • American Institute of Research accepting new patients
    Whittier California 90603 United States

Lead Scientist at UC Irvine

  • Nagasaka Misako
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 159 research publications


accepting new patients
Start Date
Completion Date
BioAtla, Inc.
Phase 2 research study
Study Type
Expecting 240 study participants
Last Updated